menu search

Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
Initial Clinical Data from Phase 2 Trial of ANX007 in Patients with Geographic Atrophy On-track for Mid-2023 Oral Small Molecule ANX1502, for Autoimmune Indications, Advances into Multi-Ascending Dose Trial Well-capitalized with Operating Runway into 2025, Including through Multiple Mid-stage and Pivotal Clinical Trial Readouts Anticipated in 2023 and 2024 BRISBANE, Calif., March 06, 2023 (GLOBE […] The post Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Antici... Read More
Posted: Mar 6 2023, 11:30
Author Name: forextv
Views: 082110

Search within

Pages Search Results: